Andere talen Egetis Therapeutics AB

Aandelen

EGTX

SE0003815604

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:23:40 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,47 ^SEK	-7,04%		+12,52%	+15,95%

03/05	Egetis Therapeutics AB (publ) rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
22/02	Egetis Therapeutics AB (publ) rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04
Egetis Therapeutics' : 2023 Annual Report published	15/04
Egetis Therapeutics’ 2023 Annual Report published	15/04
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03
Egetis Therapeutics - Continued progress in Q4	23/02
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Egetis Therapeutics : – Corporate Presentation December 2023	27/12
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19/12
Egetis’ Investor Day on December 19: Agenda and Registration Details	14/12
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13/12
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13/12
Save the Date: Egetis to host Investor Day on December 19, 2023	01/12
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10/11
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	10/11
Egetis Therapeutics - All eyes on eventful 2024	09/11
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Egetis Therapeutics AB

Aandelen

EGTX

SE0003815604

Andere talen

Filters